NCYT:LON
Novacyt SA
GBX 39.90
arrow_upward
+0.76%(+0.30) 1D
Oct 15, 5:07:37 PM GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NCYT...
Mkt. cap
34.98M
Avg. vol.
100.21K
Volume
0.00
52-wk high
GBX 86.00
52-wk low
GBX 26.60
Shares outstanding
37.66M
No. of employees
228
Mkt. cap
34.98M
Avg. vol.
100.21K
Volume
0.00
52-wk high
GBX 86.00
52-wk low
GBX 26.60
Shares outstanding
37.66M
No. of employees
228
News stories
From web sources and news partners
Trefis
·
52 minutes ago
17 S&P 500 Stocks Just Made New 52-Week Highs
Yahoo Finance
·
4 hours ago
The S&P 500 Went More Than 50 Trading Days Without a 1% Drop. That Streak Just Ended. What's Next?
BigGo Finance
·
2 hours ago
Dow Surges 556 Points as Philadelphia Semiconductor Index Extends Losing Streak to Seven Sessions; Capital Rotates into Defensive Stocks
FOREX.com
·
15 hours ago
S&P 500 Forecast: SPX falls after hot inflation and as AI debt concerns mount
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA